Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06241677
Other study ID # CIRB-2023-167-1
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 5, 2024
Est. completion date March 31, 2029

Study information

Verified date February 2024
Source Chinese University of Hong Kong
Contact Yiu Ming Bonaventure Ip
Phone +85226352152
Email bonaventureip@cuhk.edu.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Direct oral anticoagulants (DOAC) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF). All four DOACs - apixaban, dabigatran, edoxaban, rivaroxaban - were associated with lower risks of major bleeding compared to warfarin. Listed as core essential medicines by the World Health Organization, DOAC prescriptions have been surging worldwide. In Hong Kong, approximately 80,000 patients received DOACs from January 2009 through December 2022 according to the Hospital Authority registry. The widespread DOAC usage had created DOAC-specific clinical dilemmas that lack evidence-based treatment despite twenty years of prescribing experience. Ischemic stroke despite DOAC (IS-DOAC), in particular, may occur in up to 6% of DOAC users annually. Due to the in vivo anticoagulation effect, there had been concerns of intracerebral bleeding (ICH) with intravenous thrombolytic therapy (IVT) for acute IS-DOAC. Under the current guideline recommendations, most acute IS-DOAC are contraindicated to IVT (see Intravenous thrombolytic therapy), which resulted in only a small proportion of acute ISDOAC patients being able to receive IVT even if presented early. Nonetheless, our group found that majority of patients had a DOAC level of <50ng/mL only 24 hours after DOAC cessation (see work done by us), a level deemed clinically negligible and safe for thrombolytic therapy. Together with evolving clinical evidence discussed below, IS-DOAC patients maybe unnecessarily barred from IVT, thus compromised functional recovery. With robust pharmacokinetic and retrospective clinical evidence to support, it is hypothesized that IVT are safe in IS-DOAC patient. The investigators hereby propose a prospective multicenter study to determine the efficacy and safety of IVT in acute IS-DOAC.


Description:

In this prospective cohort study, the investigators aim to recruit consecutive DOAC users with IS-DOAC who meet the inclusion criteria. The investigators aim to determine the safety and efficacy of IVT among DOAC patients with acute ischemic stroke. It is hypothesized that compared to a matched cohort of patients with acute IS-DOAC excluded from IVT, IVT in IS-DOAC patients with a last-DOAC-ingestion of 12-48 hours improves neurological outcomes with an acceptable safety profile.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 260
Est. completion date March 31, 2029
Est. primary completion date December 12, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Acute ischemic stroke patients with a last-known-well to presentation time within 4.5 hours 2. Patients who took any doses of apixaban (2.5mg or 5mg twice daily), dabigatran (110mg or 150mg twice daily), edoxaban (30mg or 60mg daily) or rivaroxaban (15mg or 20mg daily) 12-48 hours before presentation 3. National Institute of Health Stroke Scale (NIHSS) = 3 4. Alberta Stroke Programme Early CT (ASPECT) score = 6 5. Pre-morbid modified Rankin Scale (mRS) = 3 6. Patients aged = 18 years old Exclusion Criteria: 1. Initial CT brain showing intracranial haemorrhage 2. Contraindications to IVT according to current guideline recommendations [5], except for the use of DOAC within 12-48 hours 3. Patients with an estimated glomerular filtration rate of = 30ml/min/1.73m2 4. Patients with bleeding propensities apart from the use of DOAC, e.g. platelet count of < 100x109/L 5. Patients with significant head injury immediately prior to presentation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
alteplase or tenecteplase
Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg) or tenecteplase (0.25mg/kg, maximum dosage 25mg) will be given

Locations

Country Name City State
Hong Kong Chinese University of Hong Kong Hong Kong

Sponsors (7)

Lead Sponsor Collaborator
Chinese University of Hong Kong Pamela Youde Nethersole Eastern Hospital, Princess Margaret Hospital, Canada, Queen Mary Hospital, Hong Kong, The Queen Elizabeth Hospital, Tuen Mun Hospital, United Christian Hospital

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Presence of symptomatic intracerebral hemorrhage (ICH) As primary safety outcome. By the Heidelberg Bleeding Classification, the investigators shall categorize intracranial hemorrhages into HI1, HI2, PH1, PH2, and define symptomatic ICH as blood at any site in the brain with clinical deterioration (e.g. drowsiness and increased hemiparesis) or an increase in National Institute of Health Stroke Scale (NIHSS) score of = 4 points (scores ranging from 0-42, higher scores indicating greater severity.) up to 1 year
Primary Modified Rankin Scale (mRS) To measure the degree of disability as a primary efficacy outcome, on the scale of 0-6: 0= no symptoms at all, 6=dead 3 months after CVA
Secondary Presence of asymptomatic ICH As seen from computer tomography (CT) and magnetic resonance imaging (MRI) up to 1 year
Secondary Presence of hemorrhagic transformation As seen from computer tomography (CT) and magnetic resonance imaging (MRI) up to 1 year
Secondary Presence of malignant cerebral edema As seen from computer tomography (CT) and magnetic resonance imaging (MRI) up to 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Recruiting NCT04437251 - Effect of Brain Stimulation on Stepping Performance in Stroke Survivors and Healthy Adults N/A
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT04042961 - Reactive Balance Training and Fitness N/A
Completed NCT04567472 - HEADS: UP Online Psychological Self-management Intervention: Feasibility 2 N/A
Completed NCT00226096 - Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage N/A
Completed NCT03863678 - Effects of Dry Needling on Spasticity, Functions, Balance and Independence Level in Patients With Stroke N/A
Recruiting NCT05515237 - Constraint-Induced Movement Therapy Plus Sensory Components After Stroke N/A
Recruiting NCT04411303 - A Novel, Comprehensive Approach to Post-stroke Gait Rehabilitation Phase 1
Completed NCT04921683 - The Use of LIFUP in Chronic Disorders of Consciousness N/A
Recruiting NCT05847595 - Implicit Versus Explicit Motor Training for Upper Extremity Rehabilitation in Chronic Stroke Patients N/A
Completed NCT03956693 - Helping Ease Anxiety and Depression Following Stroke N/A
Completed NCT03561246 - Incline Training to Personalize Motor Control Interventions After Stroke N/A
Recruiting NCT04829071 - Cognition and Motor Learning Post-stroke Early Phase 1
Recruiting NCT05492513 - Constraint-Induced Movement Therapy for Adults Post-Stroke With Mild Upper Extremity Impairment N/A
Completed NCT03602313 - Biomechanical Gait Analysis in Patients Post-Stroke N/A
Recruiting NCT05174676 - Robotic Enhanced Error Training of Upper Limb Function in Post-stroke Patients N/A
Completed NCT00396708 - Wearable Robotic Functional Assistance for Stroke Rehabilitation N/A
Completed NCT02444637 - Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Phase 4
Completed NCT05311384 - Application of a Reimbursable Form of Constraint-Induced Movement Therapy for Upper Extremity N/A